NASDAQ Rare Disease Biotech CEO Sells Hundreds of Millions in Company Stock

Liquidia Corp (Nasdaq: LQDA), a rare‐disease biopharmaceutical company, saw its CEO Roger Jeffs sell 225,000 common shares in three separate open‐market transactions between May 8 and May 20.

These sales were executed through multiple accounts under a pre‐established Rule 10b5-1 trading plan, at prices ranging from approximately $41.50 to $61.30 per share.

Through this series of transactions, Jeffs realized roughly $12.6 million (about KRW 17 billion) in proceeds, while still retaining more than 1.1 million shares plus a substantial stake in unvested RSUs.

In its first‐quarter 2026 financial results announced on May 11, the company reported revenue of approximately $130 million (around KRW 180 billion) from its flagship YUTREPIA inhalation therapy and net income of about $53 million, marking its third consecutive profitable quarter. ()

According to Liquidia, since receiving U.S. FDA approval in May 2025, prescriptions of YUTREPIA have been rapidly increasing among patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. ()

Headquartered in North Carolina, Liquidia Corp develops and markets YUTREPIA, an inhaled prostacyclin formulation for patients with rare cardiopulmonary diseases. ()

Roger Jeffs has led Liquidia as CEO since 2022. He previously served as President and Co-CEO at United Therapeutics, where he oversaw the development and commercialization of therapies for rare diseases and pulmonary hypertension. ()